Search results for "hemo"

showing 10 items of 5646 documents

Novel Immune Features of the Systemic Inflammation Associated with Primary Hypercholesterolemia: Changes in Cytokine/Chemokine Profile, Increased Pla…

2018

Primary hypercholesterolemia (PH) is associated with a low grade systemic inflammation that is likely the main driver of premature atherosclerosis. Accordingly, we characterized the immune cell behaviour in PH and its potential consequences. Whole blood from 22 PH patients and 21 age-matched controls was analysed by flow cytometry to determine the percentage of leukocyte immunophenotypes, activation, and platelet-leukocyte aggregates. Plasma markers were determined by Enzyme-Linked ImmunoSorbent Assay (ELISA). The adhesion of platelet-leukocyte aggregates to tumor necrosis factor-&alpha

0301 basic medicineChemokinemedicine.medical_treatmentlcsh:Medicinechemokines030204 cardiovascular system & hematologySystemic inflammationArticleendothelial dysfunction03 medical and health sciences0302 clinical medicineleukocyte activationResposta immunitàriaprimary hypercholesterolemiaplatelet activationMedicinePlateletPlatelet activationEndothelial dysfunctionSistema cardiovascularsystemic inflammationbiologybusiness.industryMonocytelcsh:REndoteli vascularGeneral Medicinemedicine.diseasecytokines030104 developmental biologyCytokinemedicine.anatomical_structureImmunologybiology.proteinTumor necrosis factor alphamedicine.symptombusinessJournal of clinical medicine
researchProduct

COVID-19: viral–host interactome analyzed by network based-approach model to study pathogenesis of SARS-CoV-2 infection

2020

AbstractBackgroundEpidemiological, virological and pathogenetic characteristics of SARS-CoV-2 infection are under evaluation. A better understanding of the pathophysiology associated with COVID-19 is crucial to improve treatment modalities and to develop effective prevention strategies. Transcriptomic and proteomic data on the host response against SARS-CoV-2 still have anecdotic character; currently available data from other coronavirus infections are therefore a key source of information.MethodsWe investigated selected molecular aspects of three human coronavirus (HCoV) infections, namely SARS-CoV, MERS-CoV and HCoV-229E, through a network based-approach. A functional analysis of HCoV-hos…

0301 basic medicineChemokinevirusesPneumonia ViralGene regulatory networklcsh:MedicineComputational biologyVirus-host interactomemedicine.disease_causeModels BiologicalInteractomeGeneral Biochemistry Genetics and Molecular BiologyTranscriptomePathogenesis03 medical and health sciencesBetacoronavirus0302 clinical medicineViral Envelope ProteinsProtein Interaction MappingmedicineCoronavirus infectionHumansGene Regulatory NetworksPandemicsGeneCoronavirusVirus–host interactomeMembrane GlycoproteinsInnate immune systembiologySARS-CoV-2Researchlcsh:RCOVID-19virus diseasesGeneral Medicinebiochemical phenomena metabolism and nutritionVirus–host interactome ; COVID-19 ; Coronavirus infection ; Spike glycoproteinPhenotyperespiratory tract diseasescoronavirus infection; spike glycoprotein; virus-host interactome030104 developmental biologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA030220 oncology & carcinogenesisHost-Pathogen Interactionsbiology.proteinSpike glycoproteinCoronavirus InfectionsSignal TransductionJournal of Translational Medicine
researchProduct

A rare association of chronic lymphocytic leukemia with c-ANCA-positive Wegener’s granulomatosis: a case report

2016

Background Wegener’s granulomatosis is a systemic vasculitis of the small- and medium-sized vessels, produced by the action of ANCA, which involves the respiratory tract, kidneys, and eyes, with a potential for lethal evolution in the first year after diagnosis. Its association with chronic lymphocytic leukemia is rarely described in the literature, and it may be difficult to diagnose and to treat this association. Case presentation We present the case of a 73-year-old Caucasian patient, a rare case in which Wegener’s granulomatosis is associated in a patient with chronic lymphocytic leukemia, who is admitted in the Infectious Disease Department for fever, diplopia, headache, purulent and h…

0301 basic medicineChemosisMalePathologymedicine.medical_specialtyChronic lymphocytic leukemiaMucous membrane of noseCase ReportAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicineBiopsymedicinec-ANCA positiveHumansAgedmedicine.diagnostic_testbusiness.industryGranulomatosis with PolyangiitisWegener’s granulomatosismedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyOncology030220 oncology & carcinogenesisChronic lymphocytic leukemiaSurgerymedicine.symptomGranulomatosis with polyangiitisVasculitisbusinessScleritisSystemic vasculitisWorld Journal of Surgical Oncology
researchProduct

Natural Compounds: Molecular Weapons against Leukemia’s

2017

Nowadays cancer is one of the main reasons of death all over the world and it is estimated that deaths caused by cancer will grow dramatically in the next decades. Even if chemotherapy is the election therapy for solid tumors, as well as leukemias and lymphomas, cancer treatments are in continuous evolution trying to solve the problem of resistance mainly due to low accumulation of the drug in tumor cells (MDR). Natural compounds represent a valid alternative to treat several disease and recently the scientific community focus on these natural compounds and plant metabolites with therapeutic activities and low toxicities compared with synthetic ones. A combination therapy, that join convent…

0301 basic medicineChemotherapyCombination therapybusiness.industrymedicine.medical_treatmentChronic lymphocytic leukemiaCancerDiseasemedicine.diseaseBioinformaticsNatural (archaeology)03 medical and health sciencesLeukemia030104 developmental biology0302 clinical medicineSettore BIO/13 - Biologia Applicata030220 oncology & carcinogenesismedicineHairy cell leukemiaNatural Compounds leukemiabusiness
researchProduct

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct

2018

Background: Chemotherapy is currently evaluated in order to enhance the efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer. However, the mechanisms by which these drugs could...

0301 basic medicineChemotherapybiologyColorectal cancerMechanism (biology)business.industrymedicine.medical_treatmentImmunologyImmunotherapymedicine.diseaseImmune checkpoint3. Good healthBlockade03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisPD-L1medicineCancer researchbiology.proteinImmunology and AllergyCytotoxic T cellbusinessOncoImmunology
researchProduct

<p>Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data</p>

2020

Background/Aim Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and "real-life" conditions and evaluated them substance-specifically. Patients and Methods All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy seq…

0301 basic medicineCisplatinOncologyChemotherapymedicine.medical_specialtyBladder cancerMetastatic Urothelial Carcinomabusiness.industrymedicine.medical_treatmentmedicine.diseaseGemcitabinePediatric urology03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyUrothelial cell carcinoma030220 oncology & carcinogenesisInternal medicinemedicineStage (cooking)businessmedicine.drugCancer Management and Research
researchProduct

Collective behavior of quorum-sensing run-and-tumble particles in confinement

2016

We study a generic model for quorum-sensing bacteria in circular confinement. Every bacterium produces signaling molecules, the local concentration of which triggers a response when a certain threshold is reached. If this response lowers the motility then an aggregation of bacteria occurs, which differs fundamentally from standard motility-induced phase separation due to the long-ranged nature of the concentration of signal molecules. We analyze this phenomenon analytically and by numerical simulations employing two different protocols leading to stationary cluster and ring morphologies, respectively.

0301 basic medicineCollective behaviorGeneral Physics and AstronomyFOS: Physical sciencesNanotechnologyCondensed Matter - Soft Condensed MatterBacterial Physiological Phenomena01 natural sciencesSignalModels BiologicalQuantitative Biology::Cell BehaviorQuantitative Biology::Subcellular Processes03 medical and health sciences0103 physical sciencesCell Behavior (q-bio.CB)Cluster (physics)Physics - Biological Physics010306 general physicsCondensed Matter - Statistical MechanicsPhysicsStatistical Mechanics (cond-mat.stat-mech)ChemotaxisQuorum SensingQuorum sensing030104 developmental biologyChemical physicsBiological Physics (physics.bio-ph)FOS: Biological sciencesQuantitative Biology - Cell BehaviorSoft Condensed Matter (cond-mat.soft)
researchProduct

Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer

2018

Solid malignancies have been speculated to depend on cancer stem cells (CSCs) for expansion and relapse after therapy. Here we report on quantitative analyses of lineage tracing data from primary colon cancer xenograft tissue to assess CSC functionality in a human solid malignancy. The temporally obtained clone size distribution data support a model in which stem cell function in established cancers is not intrinsically, but is entirely spatiotemporally orchestrated. Functional stem cells that drive tumour expansion predominantly reside at the tumour edge, close to cancer-associated fibroblasts. Hence, stem cell properties change in time depending on the cell location. Furthermore, although…

0301 basic medicineColorectal cancerCellClone (cell biology)Mice NudeContext (language use)Colon cancer cancer stem cells tumor microenvironment.Article03 medical and health sciencesCancer stem cellCancer Stem CellsAntineoplastic Combined Chemotherapy ProtocolsmedicineTumor MicroenvironmentAnimalsHumansOsteopontin (OPN Spp1)OsteopontinStem Cell DynamicsCells CulturedCell ProliferationbiologyColon CancerGene Expression ProfilingCancerDisease RelapseTumour growthCell Biologymedicine.diseaseXenograft Model Antitumor AssaysCell biologyGene Expression Regulation NeoplasticOxaliplatinTamoxifen030104 developmental biologymedicine.anatomical_structureColonic Neoplasmsbiology.proteinNeoplastic Stem CellsTherapyStem cellCuesNature cell biology
researchProduct

Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.

2017

Abstract Background The shift from cytotoxic to targeted chemotherapy led to improved treatment outcomes in oncology. Nevertheless, many cancer patients cannot be cured from their disease because of the development of drug resistance and side effects. Purpose There is an ongoing quest for novel compounds, which raised not only the interest in natural products but also in novel combination therapy regimens. Study design In this review, we report on the inhibition epidermal growth factor receptor (EGFR) by targeted small molecules and their combination with natural products from medicinal plants. Results The combination of erlotinib with artesunate leads to synergistic inhibition of cell grow…

0301 basic medicineCombination therapymedicine.medical_treatmentPharmaceutical ScienceArtesunateDrug resistancePharmacology03 medical and health scienceschemistry.chemical_compoundErlotinib Hydrochloride0302 clinical medicineIn vivoDrug DiscoveryAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansEpidermal growth factor receptorMolecular Targeted TherapyProtein Kinase InhibitorsPharmacologyChemotherapybiologybusiness.industryCancermedicine.diseaseArtemisininsErbB Receptors030104 developmental biologyComplementary and alternative medicinechemistryArtesunate030220 oncology & carcinogenesisbiology.proteinMolecular MedicineErlotinibbusinessmedicine.drugPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct